Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

Roger J. M. Brüggemann(Radboud University Nijmegen), Jan‐Willem C. Alffenaar(University Medical Center Groningen), Nicole M. A. Blijlevens(Radboud University Nijmegen), Eliane M. Billaud(Délégation Paris 5), Jos G. W. Kosterink(University Medical Center Groningen), Paul E. Verweij(Radboud University Nijmegen), David M. Burger(Radboud University Nijmegen)
Clinical Infectious Diseases
April 10, 2009
Cited by 451Open Access
Full Text

Abstract

There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.


Related Papers

No related papers found

Powered by citation graph analysis